Literature DB >> 29750609

rs9263726 is a specific genetic marker for allopurinol-induced severe cutaneous adverse reactions in Chinese patients.

Zhiyao Chen1, Shichao Zhang1,2, Jingjing Zhang1, Yan Zhang1, Ling Xue1, Liyan Miao1.   

Abstract

AIM: Screening of an easily detectable biomarker to replace the HLA allele B variant (HLA-B*58:01) testing for predicting allopurinol-induced severe cutaneous adverse reactions (SCARs) in eastern Chinese patients.
METHODS: Six SNPs and the HLA-B*58:01 were analyzed in 17 patients with allopurinol-induced SCARs and in 151 control patients. SNPs were analyzed by pyrosequencing, and HLA-B*58:01 was evaluated by sequencing-based techniques. Consistency between sequencing-based HLA-B*58:01 testing and pyrosequencing-based rs9263726 testing was investigated in 262 individuals.
RESULTS: A significant association with allopurinol-induced SCARs was found at rs9263726 (odds ratio: 108.8) and HLA-B*58:01 (odds ratio: 108.8). The kappa values between sequencing-based HLA-B*58:01 testing and pyrosequencing-based rs9263726 testing were 0.96 (>0.75), demonstrating they were well coincident with each other.
CONCLUSION: rs9263726 was a useful surrogate of HLA-B*58:01 testing for prescreening allopurinol-induced SCARs in eastern Chinese patients.

Entities:  

Keywords:  Chinese patients; HLA-B*58:01; SCARs; allopurinol; rs9263726

Year:  2015        PMID: 29750609     DOI: 10.2217/pme.15.38

Source DB:  PubMed          Journal:  Per Med        ISSN: 1741-0541            Impact factor:   2.512


  2 in total

1.  Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines.

Authors:  Lisanne E N Manson; Jesse J Swen; Henk-Jan Guchelaar
Journal:  Front Pharmacol       Date:  2020-09-23       Impact factor: 5.810

Review 2.  Developing pharmacogenetic screening methods for an emergent country: Vietnam.

Authors:  Dinh Van Nguyen; Christopher Vidal; Hieu Chi Chu; Sheryl van Nunen
Journal:  World Allergy Organ J       Date:  2019-06-06       Impact factor: 4.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.